Expression of phosphorylated mTOR and its regulatory protein is related to biological behaviors of ameloblastoma

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 7, 2012, Pages 660-667

  Li, Ning ^a,b   Zhong, Ming ^a   Song, Ming ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b No 202 Hospital of PLA   (China)

Author keywords

Ameloblastoma; Biological behavior; Phosphorylated mTOR

Indexed keywords

EIF4EBP1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; S6 KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; AMELOBLASTOMA; ARTICLE; CELL NUCLEUS; CHILD; CYTOPLASM; FEMALE; HUMAN; JAW TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PROPORTIONAL HAZARDS MODEL; SIGNAL TRANSDUCTION; TUMOR RECURRENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; AMELOBLASTOMA; CELL NUCLEUS; CHILD; CYTOPLASM; FEMALE; HUMANS; JAW NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOSPHOPROTEINS; PHOSPHORYLATION; PROPORTIONAL HAZARDS MODELS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84866005878     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Luo HY and Li TJ. Odontogenic tumors: A study of 1309 cases in a Chinese population. Oral Oncol 2009; 45: 706-711.
2. Gomes CC, Oliveira CS and Castro WH. Clonal nature of odontogenic tumours. J Oral Pathol Med 2009; 38: 397-400.
3. Migaldi M, Sartori G and Rossi G. Tumour cell proliferation and microsatellite alterations in human ameloblastoma. Oral Oncol 2008; 44: 50-60.
4. Wang A, Zhang B, Huang H, Zhang L, Zeng D, Tao Q, Wang J and Pan C. Suppression of local invasion of ameloblastoma by inhibition of matrix metalloproteinase-2 in vitro. BMC Cancer 2008; 8: 182-192.
5. Nodit L, Barnes L, Childers E, Finkelstein S, Swalsky P and Hunt J. Allelic loss of tumor suppressor genes in ameloblastic tumors. Mod Pathol 2004; 17: 1062-1067.
6. Dai DL, Majrtinka M and Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 2005; 23: 1473-1482.
7. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S and Ghosh PM. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004; 64: 5232-5236.
8. Nakanishi K, Sakamoto M, Yamasaki S, Todo S and Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005; 103: 307-312.
9. Roca S, Quivy A, Gross-Goupil M, Bernhard JC, De Clermont H and Ravaud A. Efficacy of rechallenging metastatic renal cell carcinoma with mTOR inhibitors. Acta Oncol 2011; 50: 1135-1136
10. Min YH, Cheong JW, Kim JY, Eom JI, Lee ST, Hahn JS, Ko YW and Lee MH. Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res 2004; 64: 5225-5231.
11. Hanada M, Feng J and Hemmings BA. Structure, regulation and function of PKB/AKT- a major therapeutic target. Biochim Biophys Acta 2004; 1697-1703.
12. Kennedy SG, Kandel ES, Cross TK and Hay N. Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome C from mitochondria. Mol Cell Biol 1999; 19: 5800-5810.
13. Scheper MA, Chaisuparat R, Nikitakis NG and Sauk JJ. Expression and alterations of the PTEN/AKT/mTOR pathway in ameloblastomas. Oral Dis 2008; 14: 561-8.
14. Gagnon V, St-Germain ME, Parent S and Asselin E. Akt activity in endometrial cancer cells: regulation of cell survival through AP21. Int J Oncol 2003; 23: 803-10.
15. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL and Reddy SA. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun 2005; 331: 295-302.
16. Proud CG. The multifaceted role of mTOR in cellular stress responses. DNA Repair (Amst), 2004; 3: 927-34.
17. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J and Lowe SW. Survival signaling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-7.
18. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J and Fan Z. HER2/PI23K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003; 22: 3205-12.
19. Brognard J, Clark AS, Ni Y and Dennis PA. Akt/protein kinase B is constitutively active in nonsmall cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986-97.
20. Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi X and Jiang BH. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 2004; 287: C281-91.
21. Gao N, Zhang Z, Jiang BH and Shi X. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 2003; 310: 1124-1132.
22. ZhangD and Brodt P. Type 1 insulin2like growth factor regulatesMT12 MMP synthesis and tumor invasion via PI 32kinase/Akt signaling. Oncogene, 2003; 22: 974-982.
23. Chung TW, Lee YC and Kim CH. Hepatitis B viral HBx induces matrixmetalloproteinase 29 gene expression through activation of ERK and PI3K/AKT pathways: involvement of invasive potential. FASEB J 2004; 18: 1123-1125.
24. Laughner E, Taghavi P, Chiles K, Mahon PC and Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004.
25. Butzal M, Loges S, Schweizer M, Fischer U, Gehling UM, Hossfeld DK and Fiedler W. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res 2004; 300: 652-671.
26. Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A and Hay N. Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol, 2002; 22: 7831-7841.
27. Liu Y, Yang ML, Zhang Y and Yu BZ. The expression of mTOR and its substrates in oral squamous cell carcinoma. Hua Xi Kou Qiang Yi Xue Za Zhi. 2004; 22: 331-3.
28. Chakraborty S, Mohiyuddin SM, Gopinath KS and Kumar A. Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer. 2008; 8: 163-175.
29. Zhang X, Shu L, Hosoi H, Murti KG and Houghton PJ. Predominant nuclear localization of mammalian target of rapamycin innormal and malignant cells in culture. J Biol Chem 2002; 277: 28127-34.
30. Sabatini DM. MTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-34.
31. Bachmann RA, Kim JH, Wu AL, Park IH and Chen J. A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1. J Biol Chem 2006; 281:7357-63.